Psoriasis clinical trials, in English

Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g.

NCT01848028 · Official ClinicalTrials.gov record · Universitätsklinikum Hamburg-Eppendorf

Glucocorticoids remain to be among the most important and most frequently used anti-inflammatory and immunosuppressive or immune-modulatory acting drugs to treat rheumatic (and other) diseases. Unfortunately, glucocorticoids also exert undesired effects, especially if higher dosages have to be given over longer periods of time.

NCT02719314 · Official ClinicalTrials.gov record · Prof Dr Frank Buttgereit

The purpose of this pediatric study is to measure the drug levels, how well it works and safety of Deucravacitinib in children and adolescent participants aged 4 to \<18 years with moderate to severe plaque psoriasis. This study includes two cohorts; Cohort 1 (age 12 to \<18 years) and Cohort 2 (age 4 to \<12 years), with two parts; for each cohort.

NCT04772079 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

The objective of this registry is to compare outcomes of risankizumab-exposed pregnancies with those of pregnancies that were not exposed to risankizumab among women with plaque psoriasis, psoriatic arthritis (PsA), Crohn's disease (CD), or other conditions for which risankizumab is an FDA-approved treatment. The registry is designed to estimate the association between risankizumab and maternal, fetal, and infant outcomes by comparing the prevalence rates of these outcomes in the exposed and unexposed populations.

NCT04846959 · Official ClinicalTrials.gov record · AbbVie

Background: The immune system is the part of the body that fights infection. Some people have immune deficiencies that cause skin rashes, make them get sick often with infections, or make it difficult for their skin to heal.

NCT04864886 · Official ClinicalTrials.gov record · National Institute of Allergy and Infectious Diseases (NIAID)

The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive how well it works would lead to a more personalized approach for psoriasis treatment.

NCT05270733 · Official ClinicalTrials.gov record · University Hospitals Cleveland Medical Center

The purpose of the study is to collect different samples for molecular characterization of inflammatory skin diseases.

NCT05994976 · Official ClinicalTrials.gov record · Innovaderm Research Inc.

Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, how well it works, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies.

NCT05995353 · Official ClinicalTrials.gov record · AbbVie

In this study, participants will have 3 or 4 total study visits over approximately 10 total weeks. There is a two week medication washout period in between the 1st and 2nd visits.

NCT06399432 · Official ClinicalTrials.gov record · University Hospitals Cleveland Medical Center

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO). The main aim of the study is to know how well zasocitinib (TAK-279) works in participants with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs.

NCT06671483 · Official ClinicalTrials.gov record · Takeda

Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by an overactive immune system where the body attacks healthy tissue by mistake.

NCT06764693 · Official ClinicalTrials.gov record · AbbVie

The main purpose of this study is to assess the effectiveness of adding tirzepatide to ixekizumab therapy in standard clinical practice in participants with moderate-to-severe plaque PsO and obesity or overweight with at least 1 weight-related comorbidity.

NCT06857942 · Official ClinicalTrials.gov record · Eli Lilly and Company

This study wants to measure the how well it works, safety, and drug levels of Deucravacitinib (BMS-986165) in adolescent participants with moderate to severe plaque psoriasis

NCT06979453 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

The goal of this watch-and-measure (no experimental treatment required) study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma subtype mycosis fungoides (MF), chronic spontaneous urticaria (CSU), and cutaneous lupus erythematosus (CLE) in daily practice. Data will be compared with data from healthy volunteers.

NCT07021495 · Official ClinicalTrials.gov record · Leiden University Medical Center

Psoriasis is a chronic, systemic, inflammatory disease in which skin cells build up and develop thick, red and white scaly patches on the skin. This study will assess the change in quality of life of risankizumab treatment in adult participants with moderate to severe plaque psoriasis real-world clinical practice.

NCT07039110 · Official ClinicalTrials.gov record · AbbVie

A study to measure the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis

NCT07116967 · Official ClinicalTrials.gov record · Bristol-Myers Squibb

" This study consists of two parts: Part 1 (Dose Escalation): A randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment phase in which approximately 20 to 30 adult patients with plaque psoriasis will receive the investigational treatment for 4 weeks. Part 2 (how well it works and Safety Assessment): A randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment evaluation where approximately 200 adult patients with plaque psoriasis will undergo 12 weeks of treatment.

NCT07129382 · Official ClinicalTrials.gov record · Chipscreen Biosciences, Ltd.

This study wants to assess how well guselkumab works in improving symptoms of psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches) using muscoloskeletal ultrasound (MSUS) in a real-world setting.

NCT07220824 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

This is a Phase 1, first-in-human (FIH), randomly assigned, neither you nor the study doctors know who gets the real treatment, single-dose, parallel-group, 3-arm study to compare PK, safety, tolerability, and immunogenicity profiles of CKD-704, EU-approved Skyrizi, and US-licensed Skyrizi in healthy adult participants.

NCT07258745 · Official ClinicalTrials.gov record · Chong Kun Dang Pharmaceutical

The goal of this clinical trial is to measure the safety and effectiveness of topical diacerein in adults with psoriasis vulgaris. The primary objective of the study is to compare the proportion of participants who achieve a clinically meaningful improvement in disease severity between the topical diacerein group and the dummy treatment (placebo) group.

NCT07352306 · Official ClinicalTrials.gov record · Alaa Ashraf Muhammad Helal

An open-label extension (OLE) study to measure the long-term safety and how well it works of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.

NCT07449702 · Official ClinicalTrials.gov record · Oruka Therapeutics, Inc.

This watch-and-measure (no experimental treatment required) study aims to assess the 1-year persistence of guselkumab in adult patients with psoriatic arthritis (an inflammatory disease that affects the joints in participants with psoriasis, a skin condition that causes red, scaly patches).

NCT07532226 · Official ClinicalTrials.gov record · Janssen-Cilag Ltd.

This study aims to assess the proportion of participants with moderate-to-severe plaque psoriasis who continue treatment with guselkumab over a two-year period.

NCT07582783 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

The purpose of this post-marketing study is to assess the amount of guselkumab in breast milk of lactating women receiving guselkumab as part of their standard clinical care provided by their treating physician, for any of the approved indications. Participants can complete all study-related activities, including consent, study visits, and breast milk sample collection, from home without attending an in-person study site.

NCT07654751 · Official ClinicalTrials.gov record · Janssen Research & Development, LLC

This study is a real-world clinical research on adalimumab. The safety and how well it works of adalimumab injection for adult non-infectious uveitis are being investigated.

NCT07663331 · Official ClinicalTrials.gov record · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.

NCT07683065 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

This is a single-centre, randomly assigned, neither you nor the study doctors know who gets the real treatment, compared with a dummy treatment Phase 1 study to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of HL40626S tablets following single and multiple ascending oral doses to healthy adult participants aged 18-55 years.

NCT07736586 · Official ClinicalTrials.gov record · HighsLab Therapeutics Inc.

The main purpose of this study is to describe how well Guselkumab works after switching from Ustekinumab in participants with moderate to severe psoriasis in a routine clinical setting. A long-term skin disease that causes red, scaly and sometimes painful, itchy patches on the skin.

NCT07746583 · Official ClinicalTrials.gov record · Janssen-Cilag Kft.

The purpose of this Phase 2a/b study is: 1. to measure the how well it works, whether it is safe and how hard side effects are to live with of DDY391 in participants with psoriatic arthritis (PsA).

NCT07801495 · Official ClinicalTrials.gov record · Novartis Pharmaceuticals

The purpose of this trial is to learn about a trial medicine called MK-8644. This trial is the first time researchers will give MK-8644 to people.

NCT07850310 · Official ClinicalTrials.gov record · Merck Sharp & Dohme LLC

This study wants to measure the safety and how well it works of HS-20137 in the treatment of participants with moderate-to-severe plaque psoriasis

NCT07879885 · Official ClinicalTrials.gov record · Hansoh BioMedical R&D Company

The goal of this clinical trial is to (PART 1) to measure the whether it is safe and how hard side effects are to live with of a single subcutaneous injection of HB0017 Injection in healthy subjects with low body weight; ( PART 2) to compare the pharmacokinetics (PK) of HB0017 following single subcutaneous administration at different injection sites at the same dose.

NCT07920861 · Official ClinicalTrials.gov record · Huabo Biopharm Co., Ltd.